Pfizer Inc. (NYSE:PFE) Shares Sold by Investment Partners LTD.

Investment Partners LTD. lessened its stake in shares of Pfizer Inc. (NYSE:PFE) by 23.2% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 22,006 shares of the biopharmaceutical company’s stock after selling 6,635 shares during the quarter. Investment Partners LTD.’s holdings in Pfizer were worth $634,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in PFE. Briaud Financial Planning Inc bought a new stake in Pfizer during the third quarter worth approximately $30,000. GoalVest Advisory LLC boosted its holdings in Pfizer by 304.9% during the fourth quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock worth $31,000 after buying an additional 811 shares in the last quarter. Mizuho Securities Co. Ltd. bought a new stake in Pfizer during the third quarter worth approximately $34,000. VisionPoint Advisory Group LLC boosted its holdings in Pfizer by 52,350.0% during the third quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock worth $35,000 after buying an additional 1,047 shares in the last quarter. Finally, Tennessee Valley Asset Management Partners bought a new stake in Pfizer during the fourth quarter worth approximately $36,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Wall Street Analysts Forecast Growth

PFE has been the subject of a number of recent analyst reports. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a research note on Monday, April 15th. Guggenheim initiated coverage on shares of Pfizer in a research note on Friday, February 23rd. They issued a “buy” rating and a $36.00 price objective for the company. Argus lowered shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Finally, TD Cowen lowered shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price objective for the company. in a research note on Thursday, January 4th. Eleven equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $36.33.

Pfizer Stock Up 0.6 %

Shares of PFE stock traded up $0.14 on Friday, hitting $25.40. The company’s stock had a trading volume of 46,526,457 shares, compared to its average volume of 34,120,812. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.91 and a quick ratio of 0.69. Pfizer Inc. has a fifty-two week low of $25.20 and a fifty-two week high of $40.37. The firm’s fifty day moving average price is $26.96 and its 200-day moving average price is $28.42. The stock has a market capitalization of $143.83 billion, a price-to-earnings ratio of 70.56, a P/E/G ratio of 1.14 and a beta of 0.61.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.29. The business had revenue of $14.25 billion during the quarter, compared to analyst estimates of $14.37 billion. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. Pfizer’s quarterly revenue was down 41.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.14 EPS. Research analysts anticipate that Pfizer Inc. will post 2.24 EPS for the current year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, June 14th. Shareholders of record on Friday, May 10th will be given a dividend of $0.42 per share. This represents a $1.68 dividend on an annualized basis and a yield of 6.61%. The ex-dividend date of this dividend is Thursday, May 9th. Pfizer’s dividend payout ratio is 466.67%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.